Satellos Bioscience Share Price Today

Satellos Bioscience Q3 Results: Loss per share narrows vs estimate

Satellos Bioscience reported a quarterly loss of $0.53 per share. The result beat the analyst consensus estimate of $0.56 by 5.36%. Losses increased 35.9% YoY from $0.39 per share in the prior year.

Satellos Bioscience switches BASECAMP primary endpoint to MRI fat fraction

Satellos Bioscience Inc. changed the BASECAMP Phase 2 primary endpoint to MRI fat fraction. The switch follows FDA feedback and replaces dynamometry as the primary measure. Topline data for the 12-week placebo-controlled study is expected in Q1 2027. Fat fraction may support an accelerated approval pathway for forazapadin.

Satellos secures US patent for lead muscle drug candidate

US Patent No. 12,747,245 issued for AAK1 inhibitors including Forazapadin. Intellectual property protection extends through September 6, 2044. Eligible for Patent Term Extension following potential U.S. marketing approval. Lead candidate targets Duchenne and facioscapulohumeral muscular dystrophy.

Satellos Bioscience completes enrollment for Phase 2 DMD trial

Satellos Bioscience completed enrollment for the BASECAMP Phase 2 clinical trial. The trial evaluates forazapadin for Duchenne muscular dystrophy in ambulatory boys aged 7 to 10 years. Forazapadin is an oral small molecule designed to restore muscle regeneration. The drug candidate also targets facioscapulohumeral muscular dystrophy.

Satellos clears FDA hurdle for FSHD drug forazapadin

FDA cleared IND application for forazapadin in facioscapulohumeral muscular dystrophy (FSHD). FSHD Canada Foundation provides up to $5 million in non-dilutive financing over five quarters. Phase 2 randomized, double-blind, placebo-controlled study expected to begin in Q4 2026. Trial will evaluate safety and efficacy of oral forazapadin at 60 mg and 120 mg doses.

Satellos Q2 loss widens to $11.7M, EPS misses estimates

Satellos Bioscience's Q2 2026 results show a net loss of $11.7 million, driven by increased R&D spending on Phase 2 trials for its lead DMD candidate. The EPS miss of $(0.56) against a $(0.45) estimate underscores rising operational costs. With $61.8 million in cash, the company maintains a runway through 2027 while advancing clinical programs.